Neurvati Neurosciences is a Blackstone owned development company that focuses on late stage assets in neuroscience - the first project targets an NMDA subunit, called NR2B, for GRIN disorders

blonca9
Dec 9, 2024
1 min read

CEO Bruce Leuchter, a physician trained in neurology and psychiatry himself, describes the rational and structure behind Neurvati, and how they are looking for opportunities with proof of concept data. Plus, the unmet need in GRIN disorders and why GRIN Therapeutics is targeting it through NMDA.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Neurvati Neurosciences is a Blackstone owned development company that focuses on late stage assets in neuroscience - the first project targets an NMDA subunit, called NR2B, for GRIN disorders

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight